🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Kelley Coffman

National Institutes of Health

ORCID: 0000-0001-6906-3796

Also affiliated with Medical University of South Carolina, National Cancer Institute, Center for Cancer Research

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 8 papers. Top paper: “Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer”.

Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer

Journal for ImmunoTherapy of Cancer(2023)10.1136/jitc-2022-005640
N/A
1.4DataRank · unranked
72 citations

Changqing Xie, Yuta Myojin, Kelley Coffman, Donna Mabry Hrones, Sophie Wang +15 more

VB-111 (ofranergene obadenovec) in combination with nivolumab in patients with microsatellite stable colorectal liver metastases: a single center, single arm, phase II trial

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2023-008079
N/A
0.470DataRank · unranked
11 citations

Yuta Myojin, Cecilia Monge, Changqing Xie, Donna Mabry Hrones, Bradford J. Wood +7 more

Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinoma

Cancer Medicine(2024)10.1002/cam4.6912
N/A
0.450DataRank · unranked
12 citations

Changqing Xie, Yuta Myojin, Kelley Coffman, Donna Mabry Hrones, Gagandeep Brar +12 more

A phase I study of GPC3 targeted CAR-T cell therapy in advanced GPC3-expressing hepatocellular carcinoma (HCC).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.tps624
N/A
0DataRank · unranked
18 citations

M. Cecilia Monge B., Donna Mabry‐Hrones, Kelley Coffman, Stephanie N. Hicks, Bernadette Redd +5 more

Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinoma.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e16158
N/A
0DataRank · unranked
2 citations

Kelley Coffman, Donna Mabry Hrones, Seth M. Steinberg, Bernadette Redd, Bradford J. Wood +3 more

Altering the gut microbiome and tumor microenvironment in advanced liver cancer: A phase II study of nivolumab, tadalafil and oral vancomycin in patients with refractory primary hepatocellular carcinoma or liver dominant metastatic cancer from colorectal or pancreatic cancers

Cancer Letters(2025)10.1016/j.canlet.2025.217975
N/A
0DataRank · unranked
3 citations

Joy Awosika, Cecilia Monge, Kelley Coffman, Changqing Xie, Nebojša Skorupan +13 more

The current landscape of therapies for hepatocellular carcinoma

Carcinogenesis(2023)10.1093/carcin/bgad052
N/A
0DataRank · unranked
28 citations

Changqing Xie, Donna Mabry Hrones, Shadin Ghabra, Tim F. Greten, Cecilia Monge +1 more

Top advances of the year: Hepatobiliary cancers

Cancer(2023)10.1002/cncr.34652
N/A
0DataRank · unranked
5 citations

Tim F. Greten, Kelley Coffman